Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» PBTH's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with PBTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300381, XPAR:ALCLS, SZSE:002604, HKSE:00775, NAS:CLVS, NAS:CLDX » details
Traded in other countries:M3D.Germany,

PROLOR Biotech, Inc., formerly known as Modigene Inc., was formed on August 22, 2003 under the laws of the state of Nevada under the name LDG, Inc. It was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. The Company develops proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide is used to develop new and proprietary versions of existing therapeutic proteins that have longer life spans than therapeutic proteins without CTP. The company's products under development include human growth hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and factor IX that is offered to Hemophilia B patients to control blood clotting or coagulation. Its products under development also comprise anti-obesity peptide oxyntomodulin, factor VIIa, interferon ß and erythropoietin, and atherosclerosis and rheumatoid arthritis long-acting therapies.



Valuation & Return


More Statistics

EPS (TTM) $ -0.28
Short Percentage of Float0.00%
» More Articles for PBTH


Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)